

Arbeiten
aus der Psychiatrischen Klinik der Universität München
2012

Summe der Impact-Faktoren: 778.779

Anzahl IF-Arbeiten: 159

1. **Aichert DS, Williams SC, Möller H-J, Kumari V, Ettinger U**
Functional neural correlates of psychometric schizotypy:
an fMRI study of antisaccades.
Psychophysiology 2012; 49: 345-356. IF 3.261
2. **Aichert DS, Wöstmann NM, Costa A, Macare C, Wenig JR, Möller H-J,
Rubia K, Ettinger U**
Associations between trait impulsivity and prepotent response inhibition.
J Clin Exp Neuropsychol 2012; 34: 1016-1032. IF 1.862
3. **Allman AA, Ettinger U, Joobar R, O'Driscoll GA**
Effects of methylphenidate on basic and higher-order oculomotor functions.
J Psychopharmacol 2012; 26: 1471-1479. IF 3.374
4. **Baghai TC, Blier P, Baldwin DS, Bauer M, Goodwin GM,
Fountoulakis KN, Kasper S, Leonard BE, Malt UF, Stein DJ,
Versiani M, Möller H-J**
Executive summary of the report by the WPA section on pharmacopsychiatry on
general and comparative efficacy and effectiveness of antidepressants in the acute
treatment of depressive disorders.
Eur Arch Psychiatry Clin Neurosci 2012; 262: 13-22. IF 3.200
5. **Bandelow B, Gruber O, Falkai P**
Kurzlehrbuch Psychiatrie.
Springer, Heidelberg, 2012.

6. **Bandelow B, Sher L, Bunevicius R, Hollander E, Kasper S, Zohar J, Möller H-J, WFSBP Task Force on Mental Disorders in Primary Care and WFSBP Task Force on Anxiety Disorders, OCD and PTSD**
Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care.
Int J Psychiatry Clin Pract 2012; 16: 77-84. IF 0.448

7. **Bechdolf A, Wagner M, Ruhrmann S, Harrigan S, Putzfeld V, Pukrop R, Brockhaus-Dumke A, Berning J, Janssen B, Decker P, Bottlender R, Maurer K, Möller H-J, Gaebel W, Häfner H, Maier W, Klosterkötter J**
Preventing progression to first-episode psychosis in early initial prodromal states.
Br J Psychiatry 2012; 200: 22-29. IF 6.606

8. **Benninghoff J, van d, V, Schloesser RJ, Moessner R, Möller H-J, Rujescu D**
The complex role of the serotonin transporter in adult neurogenesis and neuroplasticity. A critical review.
World J Biol Psychiatry 2012; 13: 240-247. IF 3.571

9. **Benson PJ, Beedie SA, Shephard E, Giegling I, Rujescu D, St Clair D**
Simple viewing tests can detect eye movement abnormalities that distinguish schizophrenia cases from controls with exceptional accuracy.
Biol Psychiatry 2012; 72: 716-724. IF 9.247

10. **Bernstein H-G, Smalla K-H, Dürrschmidt D, Keilhoff G, Dobrowolny H, Steiner J, Schmitt A, Kreutz MR, Bogerts B**
Increased density of prohibitin-immunoreactive oligodendrocytes in the dorsolateral prefrontal white matter of subjects with schizophrenia suggests extraneuronal roles for the protein in the disease.
Neuromol Med 2012; 14: 270-280. IF 4.492

11. **Bis JC, DeCarli C, Smith AV, van der LF, Crivello F, Fornage M, Debette S, Shulman JM, Schmidt H, Srikanth V, Schuur M, Yu L, Choi SH, Sigurdsson S, Verhaaren BF, DeStefano AL, Lambert JC, Jack CR, Jr., Struchalin M, Stankovich J, Ibrahim-Verbaas CA, Fleischman D, Zijdenbos A, den Heijer T, Mazoyer B, Coker LH, Enzinger C, Danoy P, Amin N, Arfanakis K, van Buchem MA, de Bruijn RF, Beiser A, Dufouil C, Huang J, Cavalieri M, Thomson R, Niessen WJ, Chibnik LB, Gislason GK, Hofman A, Pikula A, Amouyel P, Freeman KB, Phan TG, Oostra BA, Stein JL, Medland SE, Vasquez AA, Hibar DP, Wright MJ, Franke B, Martin NG, Thompson PM, Enhancing Neuro Imaging Genetics through Meta-Analysis (ENIGMA) Consortium, Nalls MA, Uitterlinden AG, Au R, Elbaz A, Beare RJ, van Swieten JC, Lopez OL, Harris TB, Chouraki V, Breteler MM, De Jager PL, Becker JT, Vernooij MW, Knopman D, Fazekas F, Wolf PA, van der LA,**

- Gudnason V, Longstreth WT, Jr., Brown MA, Bennett DA, van Duijn CM, Mosley TH, Schmidt R, Tzourio C, Launer LJ, Ikram MA, Seshadri S for the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium**
Common variants at 12q14 and 12q24 are associated with hippocampal volume.
Nat Genet 2012; 44: 545-551. IF 35.209
12. **Buschert VC, Giegling I, Teipel SJ, Jolk S, Hampel H, Rujescu D, Buerger K**
Long-term observation of a multicomponent cognitive intervention in mild cognitive impairment.
J Clin Psychiatry 2012; 73: e1492-e1498. IF 5.812
13. **Busse S, Busse M, Schiltz K, Bielau H, Gos T, Brisch R, Mawrin C, Schmitt A, Jordan W, Müller UJ, Bernstein H-G, Bogerts B, Steiner J**
Different distribution patterns of lymphocytes and microglia in the hippocampus of patients with residual versus paranoid schizophrenia: Further evidence for disease course-related immune alterations?
Brain Behav Immun 2012; 26: 1273-79. IF 5.612
14. **Carrera N, Arrojo M, Sanjuan J, Ramos-Rios R, Paz E, Suarez-Rama JJ, Paramo M, Agra S, Brenlla J, Martinez S, Rivero O, Collier DA, Palotie A, Cichon S, Nothen MM, Rietschel M, Rujescu D, Stefansson H, Steinberg S, Sigurdsson E, St Clair D, Tosato S, Werge T, Stefansson K, Gonzalez JC, Valero J, Gutierrez-Zotes A, Labad A, Martorell L, Vilella E, Carracedo A, Costas J**
Association study of nonsynonymous single nucleotide polymorphisms in schizophrenia.
Biol Psychiatry 2012; 71: 169-177. IF 9.247
15. **Dabbert D, Glaser R, Grohmann R, Rüther E, Degner D**
Agranulozytose mit Todesfolge unter Aripiprazol bei einer prädisponierten Patientin.
Psychopharmakotherapie 2012; 19: 76-78. IF –
16. **Dehning S, Girma E, Gasperi S, Meyer S, Tesfaye M, Siebeck M**
Comparative cross-sectional study of empathy among first year and final year medical students in Jimma University, Ethiopia: steady state of the heart and opening of the eyes.
BMC Med Educ 2012; 12: 34. IF 1.409
17. **Dellava JE, Trace SE, Strober M, Thornton LM, Klump KL, Brandt H, Crawford S, Fichter MM, Halmi KA, Johnson C, Kaplan AS, Mitchel JE,**

- Treasure J, Woodside DB, Berrettini WH, Kaye WH, Bulik CM**
Retrospective maternal report of early eating behaviours in anorexia nervosa.
Eur Eating Dis Rev 2012; 20: 111-115. IF -
18. **Delvecchio G, Fossati P, Boyer P, Brambilla P, Falkai P, Gruber O, Hietala J, Lawrie SM, Martinot JL, McIntosh AM, Meisenzahl E, Frangou S**
Common and distinct neural correlates of emotional processing in bipolar disorder and major depressive disorder: a voxel-based meta-analysis of functional magnetic resonance imaging studies.
Eur Neuropsychopharmacol 2012; 22: 100-113. IF 4.595
19. **Demiroglu SY, Skrowny D, Quade M, Schwanke J, Budde M, Gullatz V, Reich-Erkelenz D, Jakob JJ, Falkai P, Rienhoff O, Helbing K, Heilbronner U, Schulze TG**
Managing sensitive phenotypic data and biomaterial in large-scale collaborative psychiatric genetic research projects: practical considerations.
Mol Psychiatry 2012; 17: 1180-1185. IF 14.897
20. **Derks EM, Vorstman JA, Ripke S, Kahn RS, The Schizophrenia Psychiatric Genomic Consortium, Ophoff RA**
Investigation of the genetic association between quantitative measures of psychosis and schizophrenia: a polygenic risk score analysis.
PLoS One 2012; 7: e37852. IF 3.730
21. **Drago A, Giegling I, Schäfer M, Hartmann AM, Möller H-J, de Ronchi D, Stassen HH, Serretti A, Rujescu D**
No association of a set of candidate genes on haloperidol side effects.
PLoS One 2012; 7: e44853. IF 3.730
22. **Dreimüller N, Tadic A, Dragicevic A, Boland K, Bondy B, Lieb K, Laux G, Maier W, Müller MJ, Rao ML, Rietschel M, Roschke J, Zill P, Hiemke C**
The serotonin transporter promoter polymorphism (5-HTTLPR) affects the relation between antidepressant serum concentrations and effectiveness in major depression.
Pharmacopsychiatry 2012; 45: 108-113. IF 2.109
23. **Durrenberger PF, Fernando FS, Magliozzi R, Kashefi SN, Bonnert TP, Ferrer I, Seilhean D, Nait-Oumesmar B, Schmitt A, Gebicke-Haerter J, Falkai P, Grünblatt E, Palkovits M, Parchi P, Capellari S, Arzberger T, Kretschmar H, Roncaroli F, Dexter DT, Reynolds R**
Selection of novel reference genes for use in the human central nervous system: a

- BrainNet Europe Study.
Acta Neuropathol 2012; 124: 893-903. IF 9.734
24. **Eisenbarth H, Osterheider M, Nedopil N, Stadtland C**
Recidivism in female offenders: PCL-R lifestyle factor and VRAG show predictive validity in a German sample.
Behav Sci Law 2012; 30: 575-584. IF -
 25. **Engelbregt HJ, Keeser D, Promes VHL, Verhagen-Schouten S, Deijen JB**
In-vivo EEG changes during a panic attack in a patient with specific phobia.
J Med Cases 2012; 3: 34-38. IF -
 26. **Ettinger U, Schmechtig A, Touloupoulou T, Borg C, Orrells C, Owens S, Matsumoto K, van Haren NE, Hall MH, Kumari V, McGuire PK, Murray RM, Picchioni M**
Prefrontal and striatal volumes in monozygotic twins concordant and discordant for schizophrenia.
Schizophr Bull 2012; 38: 192-203. IF 8.486
 27. **Ettinger U, Williams SC, Meisenzahl EM, Möller H-J, Kumari V, Koutsouleris N**
Association between brain structure and psychometric schizotypy in healthy individuals.
World J Biol Psychiatry 2012; 13: 544-549. IF 3.571
 28. **Euteneuer F, Schwarz MJ, Dannehl K, Hartung A, Westermann S, Rief W**
Increased soluble interleukin-2 receptor levels are related to somatic but not to cognitive-affective features in major depression.
Brain Behav Immun 2012; 26: 1244-1248. IF 5.612
 29. **Falkai P**
Die Zukunft: Psycho-Soziale Medizin.
Der Neurologe und Psychiater 2012; 13: 3-4. IF -
 30. **Falkai P**
Facetten der Psychosozialen Medizin.
Die Psychiatrie 2012; 9: 199-200. IF -

31. **Falkai P**
Zukunft der psychosozialen Medizin.
Nervenarzt 2012; 83: 1363. IF 0.804
32. **Falkai P, Möller H-J**
Biomarkers and neurobiology of schizophrenia.
Eur Arch Psychiatry Clin Neurosci 2012; 262: 363-364. IF 3.200
33. **Falkai P, Möller H-J**
Emotional status: diagnosis and treatment for severe psychiatric disorders.
Eur Arch Psychiatry Clin Neurosci 2012; 262: 1-2. IF 3.200
34. **Falkai P, Möller H-J**
From pathophysiological aspects towards unravelling the neurobiological
background of cognitive deficits.
Eur Arch Psychiatry Clin Neurosci 2012; 262: 275-276. IF 3.200
35. **Falkai P, Möller H-J**
Neurobiology of schizophrenia: from outcome to pathophysiological insights.
Eur Arch Psychiatry Clin Neurosci 2012; 262: 93-94. IF 3.200
36. **Falkai P, Möller H-J**
Psychopathology: genetics and the stress-vulnerability hypothesis.
Eur Arch Psychiatry Clin Neurosci 2012; 262: 181-182. IF 3.200
37. **Falkai P, Möller H-J**
The new impact factor in 2011 of EAPCN.
Eur Arch Psychiatry Clin Neurosci 2012; 262: 457-458. IF 3.200
38. **Falkai P, Schmitt A**
On our own behalf: a new editorial board and focus of EAPCN.
Eur Arch Psychiatry Clin Neurosci 2012; 262: 545-546. IF 3.200
39. **Fichter MM, Quadflieg N, Nisslmüller K, Lindner S, Osen B, Huber T,
Wünsch-Leiteritz W**
Does internet-based prevention reduce the risk of relapse for anorexia nervosa?
Behav Res Ther 2012; 50: 180-190. IF -
40. **Fountoulakis KN, Kasper S, Andreassen O, Blier P, Okasha A,
Severus E, Versiani M, Tandon R, Möller H-J, Vieta E**

- Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry.
Eur Arch Psychiatry Clin Neurosci 2012; 262 Suppl 1: S1-S48. IF 3.200
41. **Fountoulakis KN, Möller H-J**
Antidepressant drugs and the response in the placebo group: the real problem lies in our understanding of the issue.
J Psychopharmacol 2012; 26: 744-750 IF: 3.374
 42. **Frank J, Cichon S, Treutlein J, Ridinger M, Mattheisen M, Hoffmann P, Herms S, Wodarz N, Soyka M, Zill P, Maier W, Mössner R, Gaebel W, Dahmen N, Scherbaum N, Schmal C, Steffens M, Lucae S, Ising M, Müller-Myhsok B, Nothen MM, Mann K, Kiefer F, Rietschel M**
Genome-wide significant association between alcohol dependence and a variant in the ADH gene cluster.
Addict Biol 2012; 17: 171-180. IF 5.914
 43. **Gaebel W, Möller H-J**
European guidance – a project of the European Psychiatric Association.
Eur Psychiatry 2012 27: 65-67. IF 3.285
 44. **Genius J, Benninghoff J, Reuter N, Braun I, Giegling I, Hartmann A, Möller H-J, Rujescu D**
Dysequilibrium of neuronal proliferation and apoptosis in a pharmacological animal model of psychosis.
Methods 2012; 56: 519-527. IF 3.641
 45. **Genius J, Geiger J, Bender A, Möller H-J, Klopstock T, Rujescu D**
Creatine protects against excitotoxicity in an in vitro model of neurodegeneration.
PLoS One 2012; 7: e30554. IF 3.730
 46. **Genius J, Giegling I, Benninghoff J, Rujescu D**
Disturbed function of GABAergic interneurons in schizophrenia: relevance for medical treatment?
Curr Pharm Biotechnol 2012; 13: 1549-1556. IF 2.690
 47. **Gerber SI, Krienke UJ, Biedermann NC, Grunze H, Yolken RH, Dittmann S, Langosch JM**
Impaired functioning in euthymic patients with bipolar disorder - HSV-1 as a predictor.
Prog Neuropsychopharmacol Biol Psychiatry 2012; 36: 110-116. IF 3.552

48. **Gerrish A, Russo G, Richards A, Moskvina V, Ivanov D, Harold D, Sims R, Abraham R, Hollingworth P, Chapman J, Hamshere M, Pahwa JS, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Johnston JA, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Kolsch H, Heun R, Schurmann B, van den BH, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frolich L, Hampel H, Hull M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Davies G, Harris SE, Starr JM, Deary IJ, Al Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Muhleisen TW, Nothen MM, Moebus S, Jockel KH, Klopp N, Wichmann HE, Carrasquillo MM, Pankratz VS, Younkin SG, Jones L, Holmans PA, O'Donovan MC, Owen MJ, Williams J**
The role of variation at AbetaPP, PSEN1, PSEN2, and MAPT in late onset Alzheimer's disease.
J Alzheimers Dis 2012; 28: 377-387. IF 4.174
49. **Giegling I, Porcelli S, Balzarro B, Andrisano C, Schafer M, Möller H-J, Rujescu D, Serretti A**
Antipsychotic response in the first week predicts later efficacy.
Neuropsychobiology 2012; 66: 100-105. IF 2.371
50. **Grayton HM, Fernandes C, Rujescu D, Collier DA**
Copy number variations in neurodevelopmental disorders.
Prog Neurobiol 2012; 99: 81-91. IF 9.035
51. **Greil W, Häberle A, Haueis P, Grohmann R, Russmann S**
Pharmacotherapeutic trends in 2231 psychiatric inpatients with bipolar depression from the International AMSP Project between 1994 and 2009.
J Affect Disord 2012; 136: 534-542. IF 3.295
52. **Haeberle A, Greil W, Russmann S, Grohmann R**
Mono- and combination drug therapies in hospitalized patients with bipolar depression. Data from the European drug surveillance program AMSP.
BMC Psychiatry 2012; 12: 153. IF 2.233
53. **Halmi KA, Bellace D, Berthod S, Ghosh S, Berrettini W, Brandt HA, Bulik CM, Crawford S, Fichter MM, Johnson CL, Kaplan A, Kaye WH, Thornton L, Treasure J, Woodside DB, Strober M**
An examination of early childhood perfectionism across anorexia nervosa

subtypes.

Int J Eat Disord 2012; 45: 800-807. IF 2.877

54. **Hamilton G, Harris SE, Davies G, Liewald DC, Tenesa A, Payton A, Horan MA, Ollier WE, Pendleton N, the Genetic and Environmental Risk for Alzheimer's Disease (GERAD1) Consortium, Starr JM, Porteous D, Deary IJ**
The role of ECE1 variants in cognitive ability in old age and Alzheimer's disease risk.
Am J Med Genet B Neuropsychiatr Genet 2012; 159B: 696-709. IF 3.231

55. **Hamilton G, Killick R, the Genetic and Environmental Risk of Alzheimer's Disease (GERAD1) Consortium, the Translational Genomics Research Institute (TGen) Consortium, Lambert JC, Amouyel P, the European Alzheimer Disease Initiative (EADI), Carrasquillo MM, Pankratz VS, Graff-Radford NR, Dickson DW, Petersen RC, Younkin SG, Powell JF, Wade-Martins R**
Functional and genetic analysis of haplotypic sequence variation at the nicastrin genomic locus.
Neurobiol Aging 2012; 33: 1848-13. IF 6.166

56. **Haralanova E, Haralanov S, Beraldi A, Möller H-J, Hennig-Fast**
Subjective emotional over-arousal to neutral social scenes in paranoid schizophrenia.
Eur Arch Psychiatry Clin Neurosci 2012; 262: 59-68. IF 3.200

57. **Hartz SM, Short SE, Saccone NL, Culverhouse R, Chen L, Schwantes-An TH, Coon H, Han Y, Stephens SH, Sun J, Chen X, Ducci F, Dueker N, Franceschini N, Frank J, Geller F, Gubjartsson D, Hansel NN, Jiang C, Keskitalo-Vuokko K, Liu Z, Lyytikainen LP, Michel M, Rawal R, Rosenberger A, Scheet P, Shaffer JR, Teumer A, Thompson JR, Vink JM, Vogelzang N, Wenzlaff AS, Wheeler W, Xiao X, Yang BZ, Aggen SH, Balmforth AJ, Baumeister SE, Beaty T, Bennett S, Bergen AW, Boyd HA, Broms U, Campbell H, Chatterjee N, Chen J, Cheng YC, Cichon S, Couper D, Cucca F, Dick DM, Foroud T, Furberg H, Giegling I, Gu F, Hall AS, Hallfors J, Han S, Hartmann AM, Hayward C, Heikkila K, Hewitt JK, Hottenga JJ, Jensen MK, Jousilahti P, Kaakinen M, Kittner SJ, Konte B, Korhonen T, Landi MT, Laatikainen T, Leppert M, Levy SM, Mathias RA, McNeil DW, Medland SE, Montgomery GW, Muley T, Murray T, Nauck M, North K, Pergadia M, Polasek O, Ramos EM, Ripatti S, Risch A, Ruczinski I, Rudan I, Salomaa V, Schlessinger D, Styrkarsdottir U, Terracciano A, Uda M, Willemsen G, Wu X, Abecasis G, Barnes K, Bickeboller H, Boerwinkle E, Boomsma DI, Caporaso N, Duan J, Edenberg HJ, Francks C, Gejman PV, Gelernter J, Grabe HJ, Hops H, Jarvelin MR, Viikari J, Kahonen M, Kendler KS, Lehtimaki T, Levinson DF, Marazita ML, Marchini J, Melbye**

- M, Mitchell BD, Murray JC, Nothen MM, Penninx BW, Raitakari O, Rietschel M, Rujescu D, Samani NJ, Sanders AR, Schwartz AG, Shete S, Shi J, Spitz M, Stefansson K, Swan GE, Thorgeirsson T, Volzke H, Wei Q, Wichmann HE, Amos CI, Breslau N, Cannon DS, Ehringer M, Gruzca R, Hatsukami D, Heath A, Johnson EO, Kaprio J, Madden P, Martin NG, Stevens VL, Stitzel JA, Weiss RB, Kraft P, Bierut LJ**
 Increased genetic vulnerability to smoking at CHRNA5 in early-onset smokers.
 Arch Gen Psychiatry 2012; 69: 854-861. IF 13.772
58. **Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF, Thibaut F, Möller H-J**
 World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.
 World J Biol Psychiatry 2012; 13: 318-378. IF 3.571
59. **Haueis P, Russmann S, Zorina OI, Grohmann R, Kullak-Ublick GA, Sirot EJ, Russmann H**
 Coprescription of levodopa with antipsychotics in a population of 84,596 psychiatric inpatients from 1994 to 2008.
 Pharmacopsychiatry 2012; 45: 127-132. IF 2.109
60. **He Y, Yu Z, Giegling I, Xie L, Hartmann AM, Prehn C, Adamski J, Kahn R, Li Y, Illig T, Wang-Sattler R, Rujescu D**
 Schizophrenia shows a unique metabolomics signature in plasma.
 Transl Psychiatry 2012; 2: e149. IF -
61. **Henkel V, Casaulta F, Seemüller F, Krähenbühl S, Obermeier M, Hüsler J, Möller H-J**
 Study design features affecting outcome in antidepressant trials.
 J Affect Disord 2012; 141: 160-167. IF 3.295
62. **Herpertz S, Schnell K, Falkai P**
 Psychotherapie in der Psychiatrie.
 Kohlhammer, Stuttgart, 2012.
63. **Hollingworth P, Sweet R, Sims R, Harold D, Russo G, Abraham R, Stretton A, Jones N, Gerrish A, Chapman J, Ivanov D, Moskvina V, Lovestone S, Priotsi P, Lupton M, Brayne C, Gill M, Lawlor B, Lynch A, Craig D, McGuinness B, Johnston J, Holmes C, Livingston G, Bass NJ, Gurling H, McQuillin A, the GERAD Consortium, the National Institute on Aging Late-**

- Onset Alzheimer's Disease Family Study Group, Holmans P, Jones L, Devlin B, Klei L, Barmada MM, Demirci FY, DeKosky ST, Lopez OL, Passmore P, Owen MJ, O'Donovan MC, Mayeux R, Kamboh MI, Williams J**
Genome-wide association study of Alzheimer's disease with psychotic symptoms.
Mol Psychiatry 2012; 17: 1316-1327. IF 14.897
64. **Hudson G, Sims R, Harold D, Chapman J, Hollingworth P, Gerrish A, Russo G, Hamshere M, Moskvina V, Jones N, Thomas C, Stretton A, Holmans PA, O'Donovan MC, Owen MJ, Williams J, Chinnery PF, on behalf of the GERAD1 Consortium**
No consistent evidence for association between mtDNA variants and Alzheimer disease.
Neurology 2012; 78: 1038-1042. IF 8.249
65. **Juckel G, Karch S, Kawohl W, Kirsch V, Jäger L, Leicht G, Lutz J, Stammel A, Pogarell O, Ertl M, Reiser M, Hegerl U, Möller H-J, Mulert C**
Age effects on the P300 potential and the corresponding fMRI BOLD-signal.
Neuroimage 2012; 60: 2027-2034. IF 6.252
66. **Kästner A, Grube S, El Kordi A, Stepniak B, Friedrichs H, Sargin D, Schwitulla J, Begemann M, Giegling I, Miskowiak KW, Sperling S, Hannke K, Ramin A, Heinrich R, Gefeller O, Nave KA, Rujescu D, Ehrenreich H**
Common variants of the genes encoding erythropoietin and its receptor modulate cognitive performance in schizophrenia.
Mol Med 2012; 18: 1029-1040. IF 4.469
67. **Karch S, Heinzl S, Pogarell O, Schiepek G**
Neurobiologische Grundlagen psychotherapeutischer Verfahren: ein Überblick über methodische Anforderungen sowie Ergebnisse bei psychiatrischen Störungsbildern.
Psychotherapeut 2012; 57: 204-212. IF -
68. **Karch S, Keeser D, Pogarell O**
Treatments effects in schizophrenia: evidence from neuroimaging.
Minerva Psichiatria 2012; 53: 171-184. IF -
69. **Karch S, Pogarell O, Mulert C**
Functional magnetic resonance imaging and treatment strategies in schizophrenia.
Curr Pharm Biotechnol 2012; 13: 1622-1629. IF 2.690

70. **Karch S, Segmiller F, Hantschk I, Cerovecki A, Opgen-Rhein M, Hock B, Dargel S, Leicht G, Hennig-Fast K, Riedel M, Pogarell O**
Increased gamma oscillations during voluntary selection processes in adult patients with attention deficit/hyperactivity disorder.
J Psychiatr Res 2012; 46: 1515-1523. IF 4.066
71. **Keller MC, Simonson MA, Ripke S, Neale BM, Gejman PV, Howrigan DP, Lee SH, Lencz T, Levinson DF, Sullivan PF, The Schizophrenic Psychiatric Genome-Wide Association Study Consortium**
Runs of homozygosity implicate autozygosity as a schizophrenia risk factor.
PLoS Genet 2012; 8: e1002656. IF 8.517
72. **Kiefer F, Soyka M**
Medikamente zur Behandlung von Abhängigkeit und Entzugssymptomen
In: Gründer G, Benkert O (Hrsg.)
Handbuch der Psychopharmakotherapie.
Springer, Berlin, 2012, S. 733-749.
73. **Kim JY, Liu CY, Zhang F, Duan X, Wen Z, Song J, Feighery E, Lu B, Rujescu D, St Clair D, Christian K, Callicott JH, Weinberger DR, Song H, Ming GL**
Interplay between DISC1 and GABA signaling regulates neurogenesis in mice and risk for schizophrenia.
Cell 2012; 148: 1051-1064. IF 31.957
74. **Klöppel S, Abdulkadir A, Jack CR, Jr., Koutsouleris N, Mourao-Miranda J, Vemuri P**
Diagnostic neuroimaging across diseases.
Neuroimage 2012; 61: 457-463. IF 6.252
75. **Koller G, Zill P, Rujescu D, Ridinger M, Pogarell O, Fehr C, Wodarz N, Bondy B, Soyka M, Preuss UW**
Possible association between OPRM1 genetic variance at the 118 locus and alcohol dependence in a large treatment sample: relationship to alcohol dependence symptoms.
Alcohol Clin Exp Res 2012; 36: 1230-1236. IF 3.421
76. **Konstantinidis A, Papageorgiou K, Grohmann R, Horvath A, Engel R, Kasper S**
Increase of antipsychotic medication in depressive inpatients from 2000 to 2007: results from the AMSP International Pharmacovigilance Program.
Int J Neuropsychopharmacol 2012; 15: 449-457. IF 5.641

77. **Koutsouleris N, Borgwardt S, Meisenzahl EM, Bottlender R, Möller H-J, Riecher-Rössler A**
Disease prediction in the at-risk mental state for psychosis using neuroanatomical biomarkers: results from the FePsy study.
Schizophr Bull 2012; 38: 1234-1246. IF 8.486
78. **Koutsouleris N, Davatzikos C, Bottlender R, Patschurek-Kliche K, Scheuerecker J, Decker P, Gaser C, Möller H-J, Meisenzahl EM**
Early recognition and disease prediction in the at-risk mental states for psychosis using neurocognitive pattern classification.
Schizophr Bull 2012; 38: 1200-1215. IF 8.486
79. **Koutsouleris N, Gaser C, Patschurek-Kliche K, Scheuerecker J, Bottlender R, Decker P, Schmitt G, Reiser M, Möller H-J, Meisenzahl EM**
Multivariate patterns of brain-cognition associations relating to vulnerability and clinical outcome in the at-risk mental states for psychosis.
Hum Brain Mapp 2012; 33: 2104-2124. IF 6.878
80. **Koychev I, McMullen K, Lees J, Dadhiwala R, Grayson L, Perry C, Schmechtig A, Walters J, Craig KJ, Dawson GR, Dourish CT, Ettlinger U, Wilkinson L, Williams S, Deakin JF, Barkus E**
A validation of cognitive biomarkers for the early identification of cognitive enhancing agents in schizotypy: a three-center double-blind placebo-controlled study.
Eur Neuropsychopharmacol 2012; 22: 469-481. IF 4.595
81. **Krause DL, Müller N**
The relationship between Tourette's Syndrome and infections.
Open Neurol J 2012; 6: 124-128. IF –
82. **Krause DL, Riedel M, Müller N, Weidinger E, Schwarz MJ, Myint AM**
Effects of antidepressants and cyclooxygenase-2 inhibitor on cytokines and kynurenines in stimulated in vitro blood culture from depressed patients.
Inflammopharmacology 2012; 20: 169-176. IF -
83. **Krause DL, Wagner JK, Wildenauer A, Matz J, Weidinger E, Riedel M, Obermeier M, Gruber R, Schwarz M, Müller N**
Intracellular monocytic cytokine levels in schizophrenia show an alteration of IL-6.
Eur Arch Psychiatry Clin Neurosci 2012; 262: 393-401. IF 3.200

84. **Läge D, Egli S, Riedel M, Möller H-J**
Exploring the structure of psychopathological symptoms: a re-analysis of AMDP data by robust nonmetric multidimensional scaling.
Eur Arch Psychiatry Clin Neurosci 2012; 262: 227-238. IF 3.200
85. **Leonard BE, Schwarz M, Myint AM**
The metabolic syndrome in schizophrenia: is inflammation a contributing cause?
J Psychopharmacol 2012; 26: 33-41. IF 3.374
86. **Letmaier M, Painold A, Holl AK, Grohmann R, Vergin H**
Severe psychotic exacerbation during combined treatment with aripiprazole/haloperidol after prior treatment with risperidone.
Int J Psychiatry Clin Pract 2012; 16: 153-156. IF 0.448
87. **Letmaier M, Painold A, Holl AK, Vergin H, Engel R, Konstantinidis A, Kasper S, Grohmann R**
Hyponatraemia during psychopharmacological treatment: results of a drug surveillance programme.
Int J Neuropsychopharmacol 2012; 15: 739-748. IF 5.641
88. **Leucht S, Engel RR, Davis JM, Kissling W, Meyer Zur CK, Schmauss M, Messer T**
Equipercntile linking of the Brief Psychiatric Rating Scale and the Clinical Global Impression Scale in a catchment area.
Eur Neuropsychopharmacol 2012; 22: 501-505. IF 4.595
89. **Lieb M, Bader M, Palm U, Stief CG, Baghai TC**
Ketamininduzerte Vesikopathie.
Psychiatr Prax 2012; 39: 43-45. IF -
90. **Lieb M, Hummel I, Fürst S, Baghai TC, Mokhtari-Nejad R, Palm U**
Psychotische und Nicht-Psychotische Verleugnung der Schwangerschaft.
Fortschr Neurol Psychiatr 2012; 80: 276-79. IF 0.851
91. **Lieb M, Palm U, Jacoby D, Baghai TC, Severus E**
Mirtazapin bei Hyperemesis gravidarum.
Nervenarzt 2012; 83: 374-376. IF 0.804
92. **Liepelt R, Schneider JC, Aichert DS, Wöstmann N, Dehning S, Möller H-J, Riedel M, Dolk T, Ettinger U**

- Action blind: Disturbed self-other integration in schizophrenia.
Neuropsychologia 2012; 50: 3775-3780. IF 3.477
93. **Lindner S, Fichter MM, Quadflieg N**
Decision-making and planning in full recovery of anorexia nervosa.
Int J Eat Disord 2012; 45: 866-875. IF 2.877
94. **Luciano M, Huffman JE, Arias-Vasquez A, Vinkhuyzen AA, Middeldorp CM, Giegling I, Payton A, Davies G, Zgaga L, Janzing J, Ke X, Galesloot T, Hartmann AM, Ollier W, Tenesa A, Hayward C, Verhagen M, Montgomery GW, Hottenga JJ, Konte B, Starr JM, Vitart V, Vos PE, Madden PA, Willemsen G, Konnerth H, Horan MA, Porteous DJ, Campbell H, Vermeulen SH, Heath AC, Wright A, Polasek O, Kovacevic SB, Hastie ND, Franke B, Boomsma DI, Martin NG, Rujescu D, Wilson JF, Buitelaar J, Pendleton N, Rudan I, Deary IJ**
Genome-wide association uncovers shared genetic effects among personality traits and mood states.
Am J Med Genet B Neuropsychiatr Genet 2012; 159B: 684-695. IF 3.231
95. **Luciano M, Lopez LM, de Moor MH, Harris SE, Davies G, Nutile T, Krueger RF, Esko T, Schlessinger D, Toshiko T, Derringer JL, Realo A, Hansell NK, Pergadia ML, Pesonen AK, Sanna S, Terracciano A, Madden PA, Penninx B, Spinhoven P, Hartman CA, Oostra BA, Janssens AC, Eriksson JG, Starr JM, Cannas A, Ferrucci L, Metspalu A, Wright MJ, Heath AC, van Duijn CM, Bierut LJ, Raikonen K, Martin NG, Ciullo M, Rujescu D, Boomsma DI, Deary IJ**
Longevity candidate genes and their association with personality traits in the elderly.
Am J Med Genet B Neuropsychiatr Genet 2012; 159B: 192-200. IF 3.231
96. **Many N, Stickel F, Schmitt J, Stieger B, Soyka M, Frei P, Gotze O, Mullhaupt B, Geier A**
Genetic variations in bile acid homeostasis are not overrepresented in alcoholic cirrhosis compared to patients with heavy alcohol abuse and absent liver disease.
Mutagenesis 2012; 27: 567-572. IF 3.500
97. **Martins-de-Souza D**
Brazil: the country of proteomics.
Proteomics 2012; 12: 2599-2600. IF 4.132

98. **Martins-de-Souza D**
Proteomics tackling schizophrenia as a pathway disorder.
Schizophr Bull 2012; 38: 1107-1108. IF 8.486
99. **Mattheisen M, Mühleisen TW, Strohmaier J, Treutlein J, Nenadic I, Alblas M, Meier S, Degenhardt F, Herms S, Hoffmann P, Witt SH, Giegling I, Sauer H, Schulze TG, Rujescu D, Nothen MM, Rietschel M, Cichon S**
Genetic variation at the synaptic vesicle gene SV2A is associated with schizophrenia.
Schizophr Res 2012; 141: 262-265. IF 4.590
100. **Matz J, Krause DL, Dehning S, Riedel M, Gruber R, Schwarz MJ, Müller N**
Altered monocyte activation markers in Tourette's syndrome: a case-control study.
BMC Psychiatry 2012; 12: 29. IF 2.233
101. **Möller H-J**
Das "Nikolausurteil" 2011. Die grundsätzliche Bedeutung der Entscheidung des Landessozialgerichts Berlin-Brandenburg zur Festbetragsregelung für Escitalopram.
Psychopharmakotherapie 2012; 19: 1-2. IF –
102. **Möller H-J**
How close is evidence to truth in evidence-based treatment of mental disorders?
Eur Arch Psychiatry Clin Neurosci 2012; 262: 277-289. IF 3.200
103. **Möller H-J**
Pharmacotherapy of schizophrenic patients: achievements, unsolved needs, future research necessities.
Curr Pharm Biotechnol 2012; 13: 1476-89. IF 2.690
104. **Möller H-J, Bitter I, Bobes J, Fountoulakis K, Höschl C, Kasper S**
Position statement of the European Psychiatric Association (EPA) on the value of antidepressants in the treatment of unipolar depression.
Eur Psychiatry 2012; 27: 114-128. IF 3.285
105. **Möller H-J, Laux G**
Die "Nikolaus-Entscheidung" 2011 des Landessozialgerichts Berlin-Brandenburg in Sachen Cipralext-Festbetrag. Stärkung der Rechtsposition der Hersteller patenschützter Medikamente und damit eines innovativen Arzneimittelwesens in

- Deutschland.
Psychopharmakotherapie 2012; 19: 135-142. IF -
106. **Möller-Leimkühler AM, Wiesheu A**
Caregiver burden in chronic mental illness: the role of patient and caregiver characteristics.
Eur Arch Psychiatry Clin Neurosci 2012; 262: 157-166. IF 3.200
 107. **Mössner R, Schuhmacher A, Wagner M, Lennertz L, Steinbrecher A, Quednow BB, Rujescu D, Rietschel M, Maier W**
The schizophrenia risk gene ZNF804A influences the antipsychotic response of positive schizophrenia symptoms.
Eur Arch Psychiatry Clin Neurosci 2012; 262: 193-197. IF 3.200
 108. **Montag C, Brockmann EM, Lehmann A, Müller DJ, Rujescu D, Gallinat J**
Association between oxytocin receptor gene polymorphisms and self-rated 'empathic concern' in schizophrenia.
PLoS One 2012; 7: e51882. IF 3.730
 109. **de Moor MHM, Costa PT, Terracciano A, Krueger RF, deGeus EJC, Toshiko T, Penninx BWJH, Esko T, Madden PAF, Derringer J, Amin N, Willemsen G, Hottenga J-J, Distel MA, Uda M, Sanna S, Spinhoven P, Harman CA, Sullivan P, Realo A, Allik J, Heath AC, Pergadia ML, Agrawal A, Lin P, Gruzza R, Natile T, Ciullo M, Rujescu D, Giegling I, Konnte B, Widen E, Cousminer DL, Eriksson JG, Palotie A, Peltonen L, Luciano M, Tenesa A, Davies G, Lopez LM, Hansell NK, Medland SE, Ferrucci L, Schlessinger D, Montgomery GW, Wright MJ, Aulchenko YA, Janssens ACJW, Oostra BA, Metspalu, Abecasis GR, Deary IJ, Raikkönen K, Bierut LJ, Martin NG, van Duijn CM, Boomsma DI**
Meta-analysis of genome-wide association studies for personality.
Mol Psychiatry 2012; 17: 337-349. IF 14.897
 110. **Mühlau M, Winkelmann J, Rujescu D, Giegling I, Koutsouleris N, Gaser C, Arsic M, Weindl A, Reiser M, Meisenzahl EM**
Variation within the Huntington's Disease gene influences normal brain structure.
PLoS One 2012; 7: e29809 IF 3.730
 111. **Mühleisen TW, Mattheisen M, Strohmaier J, Degenhardt F, Priebe L, Schultz CC, Breuer R, Meier S, Hoffmann P, Rivandeneira F, Hofman A, Uitterlinden AG, Moebus S, Gieger C, Emeny R, Ladwig KH, Wichmann HE, Schwarz M, Kammerer-Ciernioch J, Schlosser RG, Nenadic I, Sauer H,**

- Mössner R, Maier W, Rujescu D, Lange C, Ophoff RA, Schulze TG, Rietschel M, Nothen MM, Cichon S**
 Association between schizophrenia and common variation in neurocan (NCAN), a genetic risk factor for bipolar disorder.
 Schizophr Res 2012; 138: 69-73. IF 4.590
112. **Müller JL, Nedopil N, Saimeh N, Habermeyer E, Falkai P**
 Sicherungsverwahrung - wissenschaftliche Basis und Positionsbestimmung: Was folgt nach dem Urteil des Bundesverfassungsgerichts vom 04.05.2011?
 MWV Medizinisch Wissenschaftliche Verlagsgesellschaft, Berlin, 2012.
113. **Müller N, Wagner JK, Krause D, Weidinger E, Wildenauer A, Obermeier M, Dehning S, Gruber R, Schwarz MJ**
 Impaired monocyte activation in schizophrenia.
 Psychiatry Res 2012; 198: 341-346. IF 2.456
114. **Müller N, Myint AM, Schwarz MJ**
 Inflammation in schizophrenia.
 Adv Protein Chem Struct Biol 2012; 88: 49-68. IF 3.128
115. **Müller N, Myint AM, Schwarz MJ**
 Immunological treatment options for schizophrenia.
 Curr Pharm Biotechnol 2012; 13: 1606-1613. IF 2.690
116. **Mueller S, Keeser D, Reiser MF, Teipel S, Meindl T**
 Functional and structural MR imaging in neuropsychiatric disorders,
 Part 1: imaging techniques and their application in mild cognitive impairment and Alzheimer disease.
 AJNR Am J Neuroradiol 2012; 33: 1845-1850. IF 3.167
117. **Mueller S, Keeser D, Reiser MF, Teipel S, Meindl T**
 Functional and Structural MR Imaging in Neuropsychiatric Disorders, Part 2:
 Application in Schizophrenia and Autism.
 AJNR Am J Neuroradiol 2012; 33: 2033-2037. IF 3.167
118. **Müller-Isberner R, Eucker S, Nedopil N**
 Therapie psychisch kranker Straftäter.
 In: Voderholzer U, Hohagen F (Hrsg). Therapie psychischer Erkrankungen. State of the Art.
 Urban & Fischer, München, 2012, S. 391-404.

119. **Mundt AP, Aichberger MC, Fakhriddinov S, Fayzirahmanova M, Grohmann R, Heinz A, Ivens S, Magzumova S, Sartorius N, Strohle A**
 Prescription patterns of patients diagnosed with schizophrenia in mental hospitals in Tashkent/Uzbekistan and in four German cities.
 Pharmacoepidemiol Drug Saf 2012; 21: 145-151. IF 2.897
120. **Myint AM**
 Kynurenines: from the perspective of major psychiatric disorders.
 FEBS J 2012; 279: 1375-1385. IF 4.250
121. **Myint AM, Schwarz MJ, Müller N**
 The role of the kynurenine metabolism in major depression.
 J Neural Transm 2012; 119: 245-251. IF 3.052
122. **Nedopil N**
 Behandlung psychisch kranker Straftäter.
 In: Schneider F (Hrsg.) Positionen der Psychiatrie.
 Springer, Berlin, 2012, S. 57-64.
123. **Nedopil N**
 Das Infragestellen der Schuld und die Folgen für das Strafrecht aus forensisch-psychiatrischer Sicht.
 In: Roth G, Hubig S, Bamberger G (Hrsg.)
 Schuld und Strafe. Neue Fragen. Beck, München, 2012, S. 65-75.
124. **Neodpil N**
 Die Verwahrung von als gefährlich eingeschätzten Straftätern.
 In: Klopff J, Holzbauer A (Hrsg.) Zum österreichischen Maßnahmenvollzug nach § 21 Abs 2 StGB. Forschung, Positionen und Dokumente. Neuer Wissenschaftlicher Verlag, Wien, Graz, 2012, S. 11-23.
125. **Nedopil N**
 Forensische Psychiatrie.
 In: Bockemühl J (Hrsg.) Handbuch des Fachanwalts. Strafrecht.
 Carl Heymanns Verlag, Köln, 2012, S. 1579-1610.
126. **Nedopil N**
 Forensische Psychiatrie in Deutschland.
 In: Fleischhacker WW, Hinterhuber H (Hrsg.) Lehrbuch Psychiatrie. Springer, Wien, 2012, S. 532-542.

127. **Nedopil N**
Gefährlichkeits- und Rückfallprognose.
Leading Opinions Neurologie & Psychiatrie 2012; 4: 39-41. IF -
128. **Nedopil N**
Paradigmenwechsel vom Primat der Freiheit zum Primat der Sicherheit.
Neurotransmitter 2012; 3: 24-26. IF -
129. **Nedopil N**
Patientenverfügung – Besonderheiten in der Psychiatrie.
In: Borasio GD, Heßler H-J, Jox RJ, Meier C (Hrsg.)
Patientenverfügung, das neue Gesetz in der Praxis.
Kohlhammer, Stuttgart, 2012, S. 123-128.
130. **Nedopil N**
Standardisierte Dokumentation als Methode der Qualitätssicherung.
Forens Psychiatr Psychol Kriminol 2012; 6: 221-226. IF -
131. **Nedopil N, Gunn J, Thomson L**
Teaching forensic psychiatry in Europe.
Crim Behav Ment Health 2012; 22: 238-246. IF -
132. **Nedopil N, Löprich-Zerbes R, Stübner S**
Delinquenzrisiko bei Schizophrenie. Gefährlichkeits- und Rückfallprognose.
Neurologie & Psychiatrie 2012; 4: S. ? IF -
133. **Nedopil N, Müller JL**
Forensische Psychiatrie. Thieme, Stuttgart, 2012.
134. **Nedopil N,**
Forschungsbedarf und Ausblick.
In: Voderholzer U, Hohagen F (Hrsg). Therapie psychischer Erkrankungen –
State of the art.
Urban & Fischer, München, 2012, S. 403-404.
135. **Nothdurfter C, Baghai TC, Schüle C, Rupprecht R**
Translocator protein (18 kDa) (TSPO) as a therapeutic target for anxiety and
neurologic disorders.
Eur Arch Psychiatry Clin Neurosci 2012; 262 Suppl 2: S107-S112.
IF 3.200

136. **Nothdurfter C, Giegling I, Konte B, Hartmann AM, Konnerth H, Friedl M, Rammes G, Rupprecht R, Rujescu D**
Lack of association of the 5-HT(3A) receptor with schizophrenia.
Am J Med Genet B Neuropsychiatr Genet 2012; 159B: 310-315. IF 3.231
137. **Nothdurfter C, Rammes G, Baghai TC, Schüle C, Schumacher M, Papadopoulos V, Rupprecht R**
Translocator protein (18 kDa) as a target for novel anxiolytics with a favourable side-effect profile.
J Neuroendocrinol 2012; 24: 82-92. IF 3.331
138. **O'Dwyer L, Lamberton F, Matura S, Scheibe M, Miller J, Rujescu D, Prvulovic D, Hampel H**
White matter differences between healthy young ApoE4 carriers and non-carriers identified with tractography and support vector machines.
PLoS One 2012; 7: e36024. IF 3.730
139. **O'Dwyer L, Lamberton F, Matura S, Tanner C, Scheibe M, Miller J, Rujescu D, Prvulovic D, Hampel H**
Reduced hippocampal volume in healthy young ApoE4 carriers: an MRI study.
PLoS One 2012; 7: e48895. IF 3.730
140. **Palm U**
Centenary of schizophrenia: Should the term survive "togo shiccou sho" and "saliency syndrome"?
Asia-Pacific Psychiatry 2012; 4: 228-232. IF 0.467
141. **Palm U, Lieb M**
Schizophrenie - mehr als nur eine "Störung der Einheit des Selbst".
Nervenarzt 2012; 83: 387-388. IF 0.804
142. **Palm U, Schiller C, Fintescu Z, Obermeier M, Keeser D, Reisinger E, Pogarell O, Nitsche MA, Möller H-J, Padberg F**
Transcranial direct current stimulation in treatment resistant depression: a randomized double-blind, placebo-controlled study.
Brain Stimul 2012; 5: 242-251. IF 4.538
143. **Palm U, Schwarznau A, Lieb M**
Anorektale Fremdkörper - eine rein chirurgische Fragestellung?
Psychiat Prax 2012; 39: 296-298. IF -

144. **Peters O, Lorenz D, Fesche A, Schmidtke K, Hull M, Perneckzy R, Rütther E, Möller H-J, Jessen F, Maier W, Kornhuber J, Jahn H, Luckhaus C, Gertz HJ, Schröder J, Pantel J, Teipel S, Wellek S, Frölich L, Heuser I**
A combination of galantamine and memantine modifies cognitive function in subjects with amnesic MCI.
J Nutr Health Aging 2012; 16: 544-548. IF 2.394
145. **Petrovsky N, Ettinger U, Quednow BB, Walter H, Schnell K, Kessler H, Mössner R, Maier W, Wagner M**
Nicotine differentially modulates antisaccade performance in healthy male non-smoking volunteers stratified for low and high accuracy.
Psychopharmacology (Berl) 2012; 221: 27-38. IF 4.061
146. **Pfeiffer O, Degner D, Sirot EJ, Rütther E, Schmid C, Franz M**
Risiken einer Mehrfachkombination von Arzneimitteln in der Gerontopsychiatrie.
Psychopharmakotherapie 2012; 19: 143-146. IF -
147. **Pfennig A, Bschor T, Baghai T, Bräunig P, Brieger P, Falkai P, Geissler D, Gielen R, Giesler H, Gruber O, Kopp I, Meyer TD, Möhrmann KH, Muche-Borowski C, Padberg F, Scherk H, Strech D, Bauer M**
S3-Leitlinie zur Diagnostik und Therapie bipolarer Störungen.
Entwicklungsprozess und wesentliche Empfehlungen.
Nervenarzt 2012; 83: 568-86. IF 0.804
148. **Plewnia C, Padberg F**
Transkranielle und invasive Hirnstimulationsverfahren bei Depressionen.
Nervenarzt 2012; 83: 1006-1012. IF 0.804
149. **Pogarell O, Hensch T, Hegerl U**
Elektroenzephalographie in der Psychopharmakotherapie
In: Gründer G, Benkert O (Hrsg.)
Handbuch der Psychopharmakotherapie. Springer, Berlin, 2012.
150. **Pogarell O, Koch W, Karch S, Dehning S, Müller N, Tatsch K, Poepperl G, Möller H-J**
Dopaminergic neurotransmission in patients with schizophrenia in relation to positive and negative symptoms.
Pharmacopsychiatry 2012; 45 Suppl 1: S36-S41. IF 2.109
151. **Premkumar P, Ettinger U, Inchley-Mort S, Sumich A, Williams SC, Kuipers E, Kumari V**

- Neural processing of social rejection: the role of schizotypal personality traits.
Hum Brain Mapp 2012; 33: 695-706. IF 6.878
152. **Preuss UW, Zimmermann J, Schultz G, Watzke A, Schmidt P, Löhnert B, Soyka M**
Risk profiles of treatment noncompletion for inpatients and outpatients undergoing alcohol disorder rehabilitation treatment.
Subst Abuse Rehabil 2012; 3: 35-42. IF -
153. **Radenbach K, Falkai P**
Probleme der Gesundheitsversorgung - Erfahrungen aus dem ärztlichen Alltag: Psychiatrie und Psychotherapie.
In: Schumpelick V, Vogel B (Hrsg.)
Gesundheitssystem im Umbruch. Herder, Freiburg, 2012, S. 136-146.
154. **Riedel M, Leucht S, Rütther E, Schmauß M, Möller H-J**
Critical trial-related criteria in acute schizophrenia studies.
Eur Arch Psychiatry Clin Neurosci 2012; 262: 151-155. IF 3.200
155. **Riedel M, Mayr A, Seemüller F, Maier W, Klingberg S, Heuser I, Klosterkötter J, Gastpar M, Schmitt A, Sauer H, Schneider F, Gaebel W, Jäger M, Möller H-J, Schennach-Wolff R**
Depressive symptoms and their association with acute treatment outcome in first-episode schizophrenia patients: comparing treatment with risperidone and haloperidol.
World J Biol Psychiatry 2012; 13: 30-38. IF 3.571
156. **Riegg F, Pogarell O**
Alkoholmissbrauch und Alkoholabhängigkeit bei Kindern und Jugendlichen in Deutschland.
Pädiat praxis 2012; 79: 137-145. IF -
157. **Rietschel M, Mattheisen M, Degenhardt F, GROUP Investigators, Mühleisen TW, Kirsch P, Esslinger C, Herms S, Demontis D, Steffens M, Strohmaier J, Haenisch B, Breuer R, Czerski PM, Giegling I, Strengman E, Schmael C, Mors O, Mortensen PB, Hougaard DM, Orntoft T, Kapelski P, Priebe L, Basmanav FB, Forstner AJ, Hoffmann P, Meier S, Nikitopoulos J, Moebus S, Alexander M, Mössner R, Wichmann H-E, Schreiber S, Rivandeneira F, Hofman A, Uitterlinden AG, Wienker TF, Schumacher J, Hauser J, Maier W, Conator RM, Erk S, Schulz TG, SGENE-plus Consortium, Craddock N, Owen MJ, O'Donovan MC, Borglum AD, Rujescu D, Walter H, Meyer-Lindenberg A, Möthen MM, Ophoff RA, Cichon S**

- Association between genetic variation in a region on chromosome 11 and schizophrenia in large samples from Europe.
Mol Psychiatry 2012; 17: 906-17. IF 14.897
158. **Rominger A, Cumming P, Xiong G, Koller G, Boning G, Wulff M, Zwergal A, Forster S, Reilhac A, Munk O, Soyka M, Wangler B, Bartenstein P, la Fougere C, Pogarell O**
[18F]Fallypride PET measurement of striatal and extrastriatal dopamine D 2/3 receptor availability in recently abstinent alcoholics.
Addict Biol 2012; 17: 490-503. IF 5.914
159. **Rujescu D**
Schizophrenia Genes: On the Matter of their convergence.
Curr Top Behav Neurosci 2012. IF -
160. **Rujescu D, Genius J, Benninghoff J, Giegling I**
Current progress in the genetic research of schizophrenia: relevance for drug discovery?
Curr Pharm Biotechnol 2012; 13: 1614-1621. IF 2.690
161. **Rujescu D, Giegling I**
Genetische Risikofaktoren für suizidales Verhalten und intermediäre Phänotypen.
Suizidprophylaxe 2012; 39: 24-30. IF -
162. **Schaaff N, Karch S, Segmiller F, Koch W, Reicherzer M, Mulert C, Hegerl U, Juckel G, Pogarell O**
Loudness dependence of auditory evoked potentials in patients with borderline personality disorder - impact of psychopathology.
Psychiatry Res 2012; 199: 181-187. IF 2.456
163. **Schaub A**
Kognitiv-psychoedukative Gruppentherapie: Einführung und Integration in die Klinik von 1995 bis 2012.
In: Maragkos M (Hrsg.) Begegnung, Dialog und Integration. Festschrift für Prof. Dr. Willi Butollo. dgvt Verlag, Tübingen, 2012, S. 109-122.
164. **Schaub A, Möller H-J**
Implementierung verhaltenstherapeutischer Ansätze in den Alltag einer Psychiatrischen Universitätsklinik.
In: Siegel, J, Schmelzer, D, Mackinger H (Hrsg.)
Horizonte der Klinischen Psychologie und Psychotherapie.

Festschrift für Hans Reinecker.
Pabst Science Publisher, Lengerich, 2012, S. 281-290.

165. **Schennach R, Meyer S, Seemüller F, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rüter E, Klingberg S, Gastpar M, Möller H-J, Riedel M**
Insight in schizophrenia-course and predictors during the acute treatment phase of patients suffering from a schizophrenia spectrum disorder.
Eur Psychiatry 2012; 27: 625-633. IF 3.285

166. **Schennach R, Meyer S, Seemüller F, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rüter E, Klingberg S, Gastpar M, Musil R, Möller H-J, Riedel M**
Response trajectories in "real-world" naturalistically treated schizophrenia patients.
Schizophr Res 2012; 139: 218-224. IF 4.590

167. **Schennach R, Musil R, Möller H-J, Riedel M**
Functional outcomes in schizophrenia: employment status as a metric of treatment outcome.
Curr Psychiatry Rep 2012; 14: 229-236. IF 3.230

168. **Schennach R, Obermeier M, Meyer S, Jager M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Ruther E, Klingberg S, Gastpar M, Seemüller F, Möller H-J, Riedel M**
Predictors of relapse in the year after hospital discharge among patients with schizophrenia.
Psychiatr Serv 2012; 63: 87-90. IF 2.013

169. **Schennach R, Obermeier M, Seemüller F, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rüter E, Klingberg S, Gastpar M, Riedel M, Möller H-J**
Evaluating depressive symptoms in schizophrenia: a psychometric comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale.
Psychopathology 2012; 45: 276-285. IF 1.615

170. **Schennach R, Riedel M, Musil R, Möller H-J**
Treatment response in first-episode schizophrenia.
Clin Psychopharmacol Neurosci 2012; 10: 78-87. IF -
171. **Schennach R, Riedel M, Obermeier M, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Ruther E, Klingberg S, Gastpar M, Seemüller F, Möller H-J**
Remission and recovery and their predictors in schizophrenia spectrum disorder: results from a 1-year follow-up naturalistic trial.
Psychiatr Q 2012; 83: 187-207. IF -
172. **Schennach R, Riedel M, Seemüller F, Dehning S, Möller H-J**
Existieren Schwellenwerte für klinische Relevanz? Exemplarische Darstellung von Wirksamkeitsunterschieden bei Escitalopram im Vergleich mit anderen Antidepressiva.
Psychopharmakotherapie 2012; 19: 10-17. IF -
173. **Schennach R, Zill P, Obermeier M, Hauer D, Dehning S, Cerovecki A, Opgen-Rhein M, Musil R, Spellmann I, Matz J, Krause D, Seemüller F, Müller N, Möller H-J, Bondy B, Riedel M**
The CNR1 gene in depression and schizophrenia - is there an association with early improvement and response?
Psychiatry Res 2012; 196: 160. IF 2.456
174. **Schiepek G, Karch S, Tominschek I, Pogarell O**
Neurobiologische Korrelate der Psychotherapie von Zwangsstörungen.
Psychotherapeut 2012; 57: 234-240. IF -
175. **Schmitt A, Falkai P**
Post-mortem findings in mood disorders, nightmares and therapeutic approaches of psychiatric diseases.
Eur Arch Psychiatry Clin Neurosci 2012; 262: 635-636. IF 3.200
176. **Schmitt A, Falkai P**
Schizophrenia: from risk genes to outcome and comorbidity.
Eur Arch Psychiatry Clin Neurosci 2012; 262: 547-548. IF 3.200
177. **Schmitt A, Gruber O, Falkai P**
Selected issues of the DGPPN Congress in 2011.
Eur Arch Psychiatry Clin Neurosci 2012; 262 Suppl 2: S49-S50. IF 3.200

178. **Schmitt A, Leonardi-Essmann F, Durrenberger PF, Wichert SP, Spanagel R, Arzberger T, Kretschmer H, Zink M, Herrera-Marschitz M, Reynolds R, Rossner MJ, Falkai P, Gebicke-Haerter PJ**
Structural synaptic elements are differentially regulated in superior temporal cortex of schizophrenia patients.
Eur Arch Psychiatry Clin Neurosci 2012; 262: 565-577. IF 3.200
179. **Schmitt GJ, Dresel S, Frodl T, la Fougère C, Boerner R, Hahn K, Möller H-J, Meisenzahl EM**
Dual-isotope SPECT imaging of striatal dopamine: a comparative study between never-treated and haloperidol-treated first-episode schizophrenic patients.
Eur Arch Psychiatry Clin Neurosci 2012; 262: 183-191. IF 3.200
180. **Schuhmacher A, Becker T, Rujescu D, Quednow BB, Lennertz L, Wagner M, Benninghoff J, Rietschel M, Häfner H, Franke P, Wölwer W, Gaebel W, Maier W, Mössner R**
Investigation of tryptophan hydroxylase 2 (TPH2) in schizophrenia and in the response to antipsychotics.
J Psychiatr Res 2012; 46: 1073-1080. IF 4.066
181. **Seemüller F, Lewitzka U, Bauer M, Meyer S, Musil R, Schennach R, Riedel M, Doucette S, Möller H-J**
The relationship of akathisia with treatment emergent suicidality among patients with first-episode schizophrenia treated with Haloperidol or Risperidone.
Pharmacopsychiatry 2012; 45: 292-296. IF 2.109
182. **Seemüller F, Möller H-J, Dittmann S, Musil R**
Is the efficacy of psychopharmacological drugs comparable to the efficacy of general medicine medication?
BMC Med 2012; 10: 17. IF 6.679
183. **Seemüller F, Riedel M, Obermeier M, Schennach-Wolff R, Spellmann I, Meyer S, Bauer M, Adli M, Kronmüller K, Ising M, Brieger P, Laux G, Bender w, Heuser I, Zeiler J, Gaebel W, Möller H-J**
The validity of self-rated psychotic symptoms in depressed inpatients.
Eur Psychiatry 2012; 27: 547-552. IF 3.285
184. **Seemüller F, Schennach R, Mayr A, Musil R, Jäger M, Maier W, Klingenberg S, Heuser I, Klosterkötter J, Gastpar M, Schmitt A, Schlosser**

- R, Schneider F, Ohmann C, Lewitzka U, Gaebel W, Möller HJ, Riedel M**
Akathisia and suicidal ideation in first-episode schizophrenia.
J Clin Psychopharmacol 2012; 32: 694-698. IF 3.513
185. **Seemüller F, Segmiller F, Obermeier M, Möller H-J**
Was Psychatriepatienten den Schlaf raubt.
MMW Fortschr Med 2012; 154: 53-56. IF –
186. **Severus E, Schaaff N, Möller H-J**
State of the art: Treatment of bipolar disorders.
CNS Neurosci Ther 2012; 18: 214-218. IF 4.458
187. **Severus E, Seemüller F, Berger M, Dittmann S, Obermeier M, Pfennig A, Riedel M, Frangou S, Möller H-J, Bauer M**
Mirroring everyday clinical practice in clinical trial design: a new concept to improve the external validity of randomized double-blind placebo-controlled trials in the pharmacological treatment of major depression.
BMC Med 2012; 10: 67. IF 6.679
188. **Shi H, Belbin O, Medway C, Brown K, Kalsheker N, Carrasquillo M, Proitsi P, Powell J, Lovestone S, Goate A, Younkin S, Passmore P, the Genetic and Environmental Risk for Alzheimer's Disease (GERAD1) Consortium, Morgan K, for the Alzheimer's Research UK (ARUK) Consortium**
Genetic variants influencing human aging from late-onset Alzheimer's disease (LOAD) genome-wide association studies (GWAS).
Neurobiol Aging 2012; 33: 1849-18. IF 6.166
189. **Soldner J, Meindl T, Koch W, Bokde ALW, Reiser MF, Möller H-J, Bürger K, Hampel H, Teipel SJ**
Strukturelle und funktionelle neuronale Konnektivität bei der Alzheimer-Krankheit.
Nervenarzt 2012; 83: 878-887. IF 0.804
190. **Soyka M**
Alkohol und Benzodiazepine. Sucht als Flucht.
Der Informierte Arzt 2012; 10: 40-43. IF -
191. **Soyka M**
Buprenorphine and buprenorphine/naloxone soluble-film for treatment

- of opioid dependence.
Expert Opin Drug Deliv 2012; 9: 1409-1417. IF 4.869
192. **Soyka M**
Dopamine is not dopamine.
Addiction 2012; 107: 248. IF 4.577
193. **Soyka M**
Missbrauchspotenzial von Propofol - Was ist gesichert?
Suchtmed 2012; 14: 47-52. IF -
194. **Soyka M**
"Neuro-Enhancement" - die Illusion von der chemischen Optimierung.
Neurologie Psychiatrie 2012; 4: 22-24. IF -
195. **Soyka M**
Substitutionsbehandlung bei Opiatabhängigkeit. Verbesserte Prognose und Lebensqualität für Suchtkranke.
Info Neurologie & Psychiatrie 2012; 10: 23-27. IF -
196. **Soyka M, Batra A**
Benzodiazepinabhängigkeit
In: Voderholzer U, Hohagen F (Hrsg.)
Therapie psychischer Erkrankungen. State of the Art 2011/2012.
Urban & Fischer, München, 2012, S. 49-56.
197. **Soyka M, Eisenmenger W, Steinböck H**
Psychiatrische Begutachtung zur freiwilligen Kastration
In: Yundina E, Stübner S, Hollweg M, Stadtland C (Hrsg.)
Forensische Psychiatrie als interdisziplinäre Wissenschaft. Festschrift zum Geburtstag von Norbert Nedopil. Medizinisch Wissenschaftliche Verlagsgesellschaft, Berlin, 2012, S. 263-271.
198. **Soyka M, Träder A, Klotsche J, Habertur A, Buhringer G, Rehm J, Wittchen HU**
Criminal behavior in opioid-dependent patients before and during maintenance therapy: 6-year follow-up of a nationally representative cohort sample.
J Forensic Sci 2012; 57: 1524-1530. IF 1.244
199. **Spellmann I, Riedel M, Schennach R, Seemüller F, Obermeier M, Musil R, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D,**

- Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rütther E, Klingberg S, Gastpar M, Möller H-J**
 One-year functional outcomes of naturalistically treated patients with schizophrenia.
 Psychiatry Res 2012; 198: 378-385. IF 2.456
200. **Stein JL, Medland SE, Vasquez AA, Hibar DP, Senstad RE, Winkler AM, Toro R, Appel K, Bartecek R, Bergmann O, Bernard M, Brown AA, Cannon DM, Chakravarty MM, Christoforou A, Domin M, Grimm O, Hollinshead M, Holmes AJ, Homuth G, Hottenga JJ, Langan C, Lopez LM, Hansell NK, Hwang KS, Kim S, Laje G, Lee PH, Liu X, Loth E, Lourdusamy A, Mattingsdal M, Mohnke S, Maniega SM, Nho K, Nugent AC, O'Brien C, Pampmeyer M, Putz B, Ramasamy A, Rasmussen J, Rijpkema M, Risacher SL, Roddey JC, Rose EJ, Ryten M, Shen L, Sprooten E, Strengman E, Teumer A, Trabzuni D, Turner J, van Eijk K, van Erp TG, van Tol MJ, Wittfeld K, Wolf C, Woudstra S, Aleman A, Alhusaini S, Almasy L, Binder EB, Brohawn DG, Cantor RM, Carless MA, Corvin A, Czisch M, Curran JE, Davies G, de Almeida MA, Delanty N, Depondt C, Duggirala R, Dyer TD, Erk S, Fagerness J, Fox PT, Freimer NB, Gill M, Goring HH, Hagler DJ, Hoehn D, Holsboer F, Hoogman M, Hosten N, Jahanshad N, Johnson MP, Kasperaviciute D, Kent JW, Jr., Kochunov P, Lancaster JL, Lawrie SM, Liewald DC, Mandl R, Matarin M, Mattheisen M, Meisenzahl E, Melle I, Moses EK, Muhleisen TW, Nauck M, Nothen MM, Olvera RL, Pandolfo M, Pike GB, Puls R, Reinvang I, Renteria ME, Rietschel M, Roffman JL, Royle NA, Rujescu D, Savitz J, Schnack HG, Schnell K, Seiferth N, Smith C, Steen VM, Valdes Hernandez MC, Van den HM, van der Wee NJ, van Haren NE, Veltman JA, Volzke H, Walker R, Westlye LT, Whelan CD, Agartz I, Boomsma DI, Cavalleri GL, Dale AM, Djurovic S, Drevets WC, Hagoort P, Hall J, Heinz A, Jack CR, Jr., Foroud TM, Le Hellard S, Macciardi F, Montgomery GW, Poline JB, Porteous DJ, Sisodiya SM, Starr JM, Sussmann J, Toga AW, Veltman DJ, Walter H, Weiner MW, Bis JC, Ikram MA, Smith AV, Gudnason V, Tzourio C, Vernooij MW, Launer LJ, DeCarli C, Seshadri S, Andreassen OA, Apostolova LG, Bastin ME, Blangero J, Brunner HG, Buckner RL, Cichon S, Coppola G, de Zubicaray GI, Deary IJ, Donohoe G, de Geus EJ, Espeseth T, Fernandez G, Glahn DC, Grabe HJ, Hardy J, Hulshoff Pol HE, Jenkinson M, Kahn RS, McDonald C, McIntosh AM, McMahon FJ, McMahon KL, Meyer-Lindenberg A, Morris DW, Muller-Myhsok B, Nichols TE, Ophoff RA, Paus T, Pausova Z, Penninx BW, Potkin SG, Samann PG, Saykin AJ, Schumann G, Smoller JW, Wardlaw JM, Weale ME, Martin NG, Franke B, Wright MJ, Thompson PM**
 Identification of common variants associated with human hippocampal and intracranial volumes.
 Nat Genet 2012; 44: 552-561. IF 35.209

201. **Steiner J, Bogerts B, Sarnyai Z, Walter M, Gos T, Bernstein HG, Myint AM**
 Bridging the gap between the immune and glutamate hypotheses of schizophrenia and major depression: Potential role of glial NMDA receptor modulators and impaired blood-brain barrier integrity.
 World J Biol Psychiatry 2012; 13: 482-492. IF 3.571
202. **Stübner S, Grohmann R, Schmauss M**
 Arzneimittelsicherheit in der klinischen Praxis – Teil 1: Psychopharmakologische Behandlung.
 Fortschr Neurol Psychiatr 2012; 80: 468-81. IF 0.851
203. **Sullivan P, Andreassen OA, Anney RJ, Asherson P, Ashley-Koch A, Blackwood D, Boomsma DI, Breen G, Buitelaar J, Bulik CM, Cichon S, Collier D, Corvin A, Craddock N, DeLisi LE, Ebstein R, Edenberg HJ, Estivill X, Faraone SV, Farmer AE, Fernandez-Aranda F, Flint J, Foroud T, Franke B, Gelernter J, Gill M, Grabe HJ, Hamilton SP, Hickie IB, Hoogendijk W, Jablensky A, Kalaydjieva L, Kaprio J, Kas M, Keller M, Kelsoe J, Kendler KS, Kennedy M, Kent L, Klump K, Knowles JA, Levinson DF, Lewis CM, Lichtenstein P, Lucae S, Martin NG, McCarroll S, McGough J, McGrath JJ, McGuffin P, Mitchell P, Mowry B, Muglia P, Müller-Myhsok B, Neale B, Nöthen M, Nurnberger JI, Oades RD, O'Donovan M, Ophoff R, Owen M, Pato CN, Pato MT, Penninx BW, Perlis RH, Porjesz B, Posthuma D, Potash JB, Preisig M, Reichborn-Kjennerud T, Rice JP, Rietschel M, Riley B, Ripke S, Rothenberger A, Rujescu D, Santangelo SL, Schachar R, Schellenberg GD, Scherer SW, Schofield P, Schulze TG, Sklar P, Smoller JW, Stefansson H, Stefansson K, Sullivan P, Todorov A, Tozzi F, Tzeng JY, van den Oord EJ, Vorstman JA, Wang K, Weissman MM, Werge T, Wray NR, Zeggini E**
 Don't give up on GWAS.
 Mol Psychiatry 2012; 17: 2-3. IF 14.897
204. **Taylor PJ, Gunn J, Goethals K, Nedopil N**
 Can training support free movement of forensic psychiatrists between nations?
 Crim Behav Ment Health 2012; 22: 233-237. IF –
205. **Tippelt S, Stübner S, Nedopil N**
 Die psychotherapeutischen Fachambulanzen für Sexualstraftäter in München und Nürnberg – Ergebnisse der wissenschaftlichen Begleituntersuchung.
 Forum Strafvollzug. Zeitschrift für Strafvollzug und Straffälligenhilfe 2012; 61: 95-98. IF -

206. **Tretter F, an der Heiden U, Rujescu D, Pogarell O**
Computational modelling of schizophrenic symptoms. Basic issues.
Pharmacopsychiatry 2012; 45 Suppl 1: S2-S11. IF 2.109
207. **Tretter F, Pogarell O, Rujescu D, Meisenzahl EM, Mewes HW**
Computational neuropsychiatry Vol.7: Systems biology of schizophrenia.
Editorial.
Pharmacopsychiatry 2012; 45 Suppl1: S1. IF 2.109
208. **Uehara T, Itoh H, Matsuoka T, Rujescu D, Genius J, Seo T, Sumiyoshi T**
Effect of transient blockade of N-methyl-D-aspartate receptors at neonatal stage on stress-induced lactate metabolism in the medial prefrontal cortex of adult rats: role of 5-HT1A receptor agonism.
Synapse 2012; 66: 408-417. IF 2.310
209. **Vassos E, Steinberg S, Cichon S, Breen G, Sigurdsson E, Andreassen OA, Djurovic S, Morken G, Grigoriou-Serbanescu M, Diaconu CC, Czerski PM, Hauser J, Babadjanova G, Abramova LI, Muhleisen TW, Nothen MM, Rietschel M, McGuffin P, St Clair D, Gustafsson O, Melle I, Pietilainen OP, Ruggeri M, Tosato S, Werge T, Ophoff RA, Rujescu D, Borglum AD, Mors O, Mortensen PB, Demontis D, Hollegaard MV, van Winkel R, Kenis G, De Hert M, Rethelyi JM, Bitter I, Rubino IA, Golimbet V, Kiemenev LA, van den Berg LH, Franke B, Jonsson EG, Farmer A, Stefansson H, Stefansson K, Collier DA**
Replication study and meta-analysis in European samples supports association of the 3p21.1 locus with bipolar disorder.
Biol Psychiatry 2012; 72: 645-650. IF 9.247
210. **Völter C, Riedel M, Wöstmann N, Aichert DS, Lobo S, Costa A, Schmechtig A, Collier DA, Hartmann AM, Giegling I, Möller H-J, Quednow BB, Rujescu D, Kumari V, Ettinger U**
Sensorimotor gating and D2 receptor signalling: evidence from a molecular genetic approach.
Int J Neuropsychopharmacol 2012; 15: 1427-1440. IF 5.641
211. **Völter C, Strobach T, Aichert DS, Wöstmann N, Costa A, Möller H-J, Schubert T, Ettinger U**
Schizotypy and behavioural adjustment and the role of neuroticism.
PLoS One 2012; 7: e30078. IF 3.730

212. **Wasserman D, Rihmer Z, Rujescu D, Sarchiapone M, Sokolowski M, Titelman D, Zalsman G, Zemishlany Z, Carli V**
Az Európai Pszichiátriai Szövetség (European Psychiatric Association, EPA) útmutatója az öngyilkosság kezelésére és megelőzésére.
Neuropsychopharmacol Hung 2012; 14: 113-136. IF -
213. **Wasserman D, Rihmer Z, Rujescu D, Sarchiapone M, Sokolowski M, Titelman D, Zalsman G, Zemishlany Z, Carli V**
The European Psychiatric Association (EPA) guidance on suicide treatment and prevention.
Eur Psychiatry 2012; 27: 129-141. IF 3.285
214. **Werge T, Ingason A, Kirov G, Rujescu D, Sigurdsson E**
Response to boot et al. Letter.
Am J Psychiatry 2012; 169: 97. IF 14.721
215. **Yundina E, Stübner S, Hollweg M, Stadtland C**
Forensische Psychiatrie als interdisziplinäre Wissenschaft.
Festschrift zum Geburtstag von Norbert Nedopil.
Medizinisch Wissenschaftliche Verlagsgesellschaft, Berlin, 2012.
216. **Zill P, Baghai TC, Schüle C, Born C, Früstück C, Büttner A, Eisenmenger W, Varallo-Bedarida G, Rupprecht R, Möller H-J, Bondy B**
DNA methylation analysis of the angiotensin converting enzyme (ACE) gene in major depression.
PLoS One 2012; 7: e40479. IF 3.730
217. **Zunszain PA, Anacker C, Cattaneo A, Choudhury S, Musaelyan K, Myint AM, Thuret S, Price J, Pariante CM**
Interleukin-1beta: a new regulator of the kynurenine pathway affecting human hippocampal neurogenesis.
Neuropsychopharmacology 2012; 37: 939-949. IF 8.678